AXQ Capital LP Has $175,000 Stock Holdings in ImmunityBio, Inc. $IBRX

AXQ Capital LP grew its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 263.4% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 71,300 shares of the company’s stock after buying an additional 51,678 shares during the quarter. AXQ Capital LP’s holdings in ImmunityBio were worth $175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of the business. Slow Capital Inc. acquired a new position in shares of ImmunityBio in the third quarter valued at about $25,000. Truist Financial Corp bought a new stake in ImmunityBio in the 3rd quarter valued at about $27,000. Diversify Advisory Services LLC acquired a new position in shares of ImmunityBio during the 2nd quarter worth approximately $27,000. Summit X LLC acquired a new position in shares of ImmunityBio during the 2nd quarter worth approximately $28,000. Finally, Envision Financial Planning LLC bought a new position in shares of ImmunityBio during the second quarter worth approximately $28,000. Institutional investors own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on IBRX. The Goldman Sachs Group reissued a “buy” rating on shares of ImmunityBio in a research report on Monday. D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a report on Monday, February 23rd. BTIG Research boosted their price target on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. Finally, Piper Sandler increased their price objective on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, ImmunityBio has an average rating of “Moderate Buy” and an average price target of $12.60.

Insider Activity

In other ImmunityBio news, Director Barry J. Simon sold 75,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total transaction of $900,750.00. Following the sale, the director directly owned 2,850,821 shares of the company’s stock, valued at $34,238,360.21. The trade was a 2.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Christobel Selecky sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $10.00, for a total transaction of $250,000.00. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 501,967 shares of company stock worth $4,466,412. Company insiders own 69.48% of the company’s stock.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio announced completion of enrollment in its pivotal randomized Phase 2 trial of ANKTIVA plus BCG vs BCG alone in BCG‑naïve NMIBC CIS — early completion reduces timeline uncertainty for a potential label‑expanding readout and supports commercial upside for ANKTIVA. Article Title
• Positive Sentiment: Analyst/valuation commentary highlights trial progress and strong ANKTIVA commercial momentum — positive narratives that can support higher forward earnings expectations and investor confidence. Article Title
• Neutral Sentiment: ImmunityBio will host a business update and review FY‑2025 financial results on March 3 — the call could drive volatility depending on revenue, guidance, and clinical updates management provides. Article Title
• Neutral Sentiment: HC Wainwright published a Q1 earnings forecast for ImmunityBio — analyst forecasts and any accompanying model changes will influence near‑term analyst sentiment and target‑price revisions. Article Title
• Negative Sentiment: Director Barry Simon sold 75,000 shares at an average price of $12.01 (disclosed Feb 24) — insider selling can be interpreted by some investors as a signal to reduce exposure, contributing to downward pressure. Article Title
• Negative Sentiment: Reports cite significant intraday profit‑taking (one article notes a ~17% drop after an intraday high) and coverage pointing to a ~7% decline — these articles reflect short‑term selling and headline‑driven volatility that can amplify swings in the stock. Article Title Article Title

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $9.78 on Friday. ImmunityBio, Inc. has a 52-week low of $1.83 and a 52-week high of $12.43. The company has a market capitalization of $10.05 billion, a PE ratio of -25.74 and a beta of 0.16. The company has a fifty day moving average of $5.27 and a 200-day moving average of $3.38.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $38.29 million for the quarter. On average, equities analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current fiscal year.

ImmunityBio Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.